.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Transitioning pediatric patients to efanesoctocog alfa prophylaxis represents a significant advancement in the management of Haemophilia A. This novel recombinant factor VIII (FVIII) therapy offers an ultra-extended half-life. Consequently, clinicians can now provide patients with high sustained factor levels through a once-weekly dosing schedule. This study evaluates the comprehensive outcomes of switching children from traditional factor concentrates or emicizumab to this new therapeutic option.
Efanesoctocog alfa breaks the \"von Willebrand factor ceiling\" that previously limited the half-life of FVIII products. It achieves this by using a fusion protein design including XTEN polypeptides and an Fc domain. Therefore, the molecule remains in circulation much longer than standard or extended half-life products. Research demonstrates that mean factor VIII activity stays above 40 IU/dL for three days and remains above 10 IU/dL for nearly the entire week. Furthermore, this stable pharmacokinetic profile translates to superior protection against spontaneous bleeding episodes.
In a prospective observational study, researchers assessed a cohort of children transitioning to this therapy. Most patients previously relied on standard or extended half-life FVIII. However, some also transitioned from emicizumab. The results showed a significant reduction in the annualized bleed rate (ABR). Additionally, caregivers and patients reported improved musculoskeletal comfort and increased confidence in pursuing physical activities. Most importantly, the study reported no new inhibitor development, which confirms the safety profile of the drug in previously treated children.
Specifically, patients tolerated the transition process well across the pediatric unit. Clinicians observed that once-weekly infusions significantly reduced the treatment burden compared to every-other-day regimens. Moreover, the therapy's high trough levels offer a \"normal to near-normal\" window of activity for a substantial part of the week. This level of protection is particularly beneficial for active children who require robust hemostatic coverage for sports and daily play.
Yes, clinical data indicates that patients can successfully transition from emicizumab to efanesoctocog alfa. The study observed excellent hemostatic outcomes in these cases, although clinicians should monitor factor levels using appropriate assays during the transition.
No, one of the primary benefits of this treatment is the once-weekly dosing schedule. This reduction in infusion frequency significantly eases the burden on pediatric patients and their caregivers compared to traditional prophylaxis.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always consult a qualified medical professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Berrueco R et al. Comprehensive Assessment of the Transition to Efanesoctocog Alfa Prophylaxis in a Paediatric Haemophilia A Cohort. Haemophilia. 2026 May 30. doi: 10.1111/hae.70328. PMID: 42216685.
2. Malec L et al. Efanesoctocog alfa prophylaxis for children with severe hemophilia A. N Engl J Med. 2024;391(3):234-245.
3. von Drygalski A et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388(10):906-918.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study analyzes the transition of pediatric Haemophilia A patients to efanesoctocog alfa, showing improved bleed rates and patient satisfaction....
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
